Thursday, November 1, 2012
The public spat between the scientific board and management
of the Cancer Prevention & Research Institute of Texas is a
case study in how commercial and scientific interests can clash when the two
sides are not on the same page about how grants are distributed. The lesson is
that academic grant reviewers need to be aware of a foundation's commercial
development priorities in any proposal-vetting process.
Out with a
Texas hold 'em
L. SciBX 5(43);
Published online Nov. 1, 2012
1. Osherovich, L. SciBX
2. Kaiser, J. Science
336, 789-790 (2012)
3. Gilman, A.G. &
Sharp, P.A. Cancer institute can regain science community's respect. Houston
Chronicle (Oct. 12, 2012)
AND INSTITUTIONS MENTIONED
bluebird bio Inc., Cambridge, Mass.
California Institute for Regenerative Medicine, San Francisco, Calif.
Cancer Prevention & Research Institute of Texas, Austin, Texas
Massachusetts Institute of Technology, Cambridge, Mass.
Rice University, Houston, Texas
The University of Texas MD Anderson Cancer Center, Houston, Texas
The University of Texas Southwestern Medical Center, Dallas, Texas
ViaCyte Inc., San Diego, Calif.